Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Plos One|June 19, 2014
Merging national forest and national forest health inventories to obtain an integrated forest resource inventory--experiences from Bavaria, Slovenia and SwedenMarko Kovač, Arthur Bauer, Göran Ståhl
Sensors (Basel, Switzerland)|June 10, 2022
Pendulum-Based River Current Energy Converter for Hydrometric Monitoring SystemsSlim Naifar, Felix Grimmeisen, Christian Viehweger, et al.
Leukemia & Lymphoma|December 3, 2021
Comparative analysis of international prognostic indices in gray-zone lymphomaHanno M Witte, Hartmut Merz, Heinz-Wolfram Bernd, et al.
Journal of Cancer Research and Clinical Oncology|July 28, 2022
The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibitionArthur Bauer, Niklas Gebauer, Juliana Knief, et al.
Cancers|November 11, 2022
The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastro-Entero-Pancreatic (GEP-NEN) SystemNiklas Gebauer, Maria Ziehm, Judith Gebauer, et al.
Journal of Cancer Research and Clinical Oncology|August 20, 2021
Prognostic impact of nutritional and inflammation-based risk scores in follicular lymphoma in the era of anti-CD20 targeted treatment strategiesNiklas Gebauer, Britta Mengler, Svenja Kopelke, et al.
Cancers|April 14, 2026
Adenosine Pathway Activation Defines Genetically Linked Immunosuppressive Subtypes in Solid Tumor Brain MetastasesArthur Bauer, Annette Arndt, Luisa Reichenbach, et al.
International Journal of Molecular Sciences|March 13, 2024
Late Onset of Primary Hemophagocytic Lymphohistiocytosis (HLH) with a Novel Constellation of Compound Heterozygosity Involving Two Missense Variants in the PRF1 GeneAlina Stadermann, Markus Haar, Armin Riecke, et al.
Annals of Hematology|February 24, 2025
The mutational landscape and its longitudinal dynamics in relapsed and refractory classic Hodgkin lymphomaHanno Witte, Axel Künstner, Thomas Hahn, et al.
The Oncologist|July 3, 2024
Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinomaAnnette Arndt, Christian Neumann, Armin Riecke, et al.
Pageof 1